In the present study, we examined the effects of pharmacologic inhibition of myostatin with a myostatin‐blocking antibody (REGN647(27, 28)) in the skeletal muscle and bone properties of an animal model of insulin‐deficient (T1D) diabetes, with and without insulin treatment. Here, MSTN is linked to diabetes mellitus.